Tecogen Inc. (TGEN) Q3 Revenue Rose 10%, Net Loss Narrowed to $1.59M

Tecogen Inc. (TGEN) reported Q3 2026 revenue of $7.87M, up 10% YoY, with a net loss of $1.59M, narrower than the $2.13M loss in Q3 2025. However, nine-month revenue declined 8% YoY to $19.96M, and net loss widened to $5.86M. Cash position was $5.33M at Q3 end, according to the company.

Original reporting
Published Nov 11, 2026, 10:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 10:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tecogen Inc. (TGEN) Q3 Revenue Rose 10%, Net Loss Narrowed to $1.59M — source image
Decision brief

The 30-second read

$TGENNeutralMed
01

Why it matters

The earnings release provides the first public data for Q3 2026, offering traders fresh information to reassess valuation.

02

Market read

New earnings data may trigger short‑term price movement; investors will watch guidance and cash runway.

03

What to watch

Cash balance increase to $5.7M suggests better liquidity, which could support future growth initiatives.

Relevance 6/10Novelty 7/10Timing: post‑market today

Background

Tecogen Inc. provides distributed power generation solutions; the company is a micro‑cap listed on Nasdaq.

Company-level read

Ticker impact

$TGENNeutralHigh confidence
Context

Q3 2026 earnings released showing revenue up 10% YoY and net loss narrowing to $1.59M.

Expected impact

modest upside as market prices in loss narrowing, tempered by declining nine‑month revenue.

Evidence & confidence

The fresh earnings numbers are the first public disclosure; loss improvement may attract short‑term buying, while YTD decline limits upside.

Market effects

Signals modest recovery potential for small‑cap clean‑energy equipment makers.

Limited to U.S. micro‑cap investors.

Low; impact confined to Tecogen and niche sector participants.

Counterpoint

Despite loss narrowing, the continued YTD revenue decline may signal deeper demand issues.

Key entities

  • Tecogen Inc.

    US‑listed micro‑cap power generation equipment manufacturer.

Related articles

$TGENMed

TECOGEN INC. (TGEN): Third Quarter 2026 Financial Results

TECOGEN INC. (TGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tecogen Reports Third Quarter 2026 Financial Results NORTH BILLERICA, Mass., November 11, 2026 - Tecogen Inc. (NYSE American:TGEN), a leading manufacturer of clean energy products, reported revenues of $7.87 million and net loss of $1.59 million for the three months ended Septemb

$TGENMed

TECOGEN INC. (TGEN): Second Quarter 2026 Financial Results

TECOGEN INC. (TGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tecogen Reports Second Quarter 2026 Financial Results NORTH BILLERICA, Mass., August 12, 2026 - Tecogen Inc. (NYSE American:TGEN), a leading manufacturer of clean energy products, reported revenues of $5.75 million and net loss of $2.15 million for the three months ended June 30,

$NEONMed

Neonode Reports Quarter Ended September 30, 2026 Financial Results

Neonode Inc. (NEON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Press Release For Release, 9:10AM ET November 12, 2026 Neonode Reports Quarter Ended September 30, 2026 Financial Results STOCKHOLM, SWEDEN, November 12, 2026 — Neonode Inc. (NASDAQ: NEON) (“Neonode” or the “Company”) today reported financial results for the three an

$UGMed

United-Guardian 3Q 2026: Revenue $3.49M, EPS $0.2 — 10-Q Summary

United-Guardian reported 3Q 2026 revenue of $3.49M, up 54% YoY, with EPS of $0.2. Growth was driven by pharmaceuticals, cosmetic ingredients, and medical lubricants. Pharmaceutical sales rose 29% due to Renacidin formulary coverage, while cosmetic ingredient sales climbed 187% after ASI resumed purchases. Medical lubricant sales increased 20%, and cost of sales fell to 46% of revenue.